Replies to post #378556 on Amarin Corp Plc (AMRN)

[tm100]

How does Pfizer distribute lipitor in China? Perhaps an HLS type deal, with Pfizer's participation, is being worked on for China.

[bidmark]

Color me skeptical, but do you have confidence that the master strategist Kennedy thought this through before signing Edding up? If Edding doesn't have the $$ to finish the approval, not to mention paying Amarin milestones and a launch, does the agreement allow for Amarin to terminate? And what happens to the approval process in place? Does it get assigned to Amarin or another party of Amarin's choosing?

[ziploc_1]

Lizzy...Amarin was paid $15 million up front in 2015 by Eddingpharm upon the signing of a partnership for China with Amarin...In addition, Eddingpharm is a substantial company, being a partner of Pfizer in the distribution of Lipitor in China.

I understand Eddingpharm is having some trouble doing an IPO in Hong Kong, but I hope that an arrangement can be made soon so distribution in China of Vascepa can be started ASAP....If not, Amarin must look for another partner in China.

This project is important to Amarin and I hope KM can give us some details as to why it is taking so long.

[dogn]

Lizzy,

dogn, after further researching the Edding situation the last IPO filing was in 2020. Maybe that's why KM mentioned they are in talks with a few BP to partner with outside of the EU. Maybe they have written off Edding as a partner?? I hope that's accurate, amarin may have to give up a few shekels but will be worth it in order to effectively market V.
Plus the lockdown in China isn't helping the situation.

Thanks. It's plausible that Amarin may prefer to move forward in China with a different partner than Edding. Edding licensed Vascepa (pre REDUCE-IT completion) in Feb. 2015. It took them 2 years to initiate a 12 week MARINE-like Vascepa trial for VHTG in China, and 3 more years to report results and submit NDA per timeline at eddingpharm.com/EN/research (link seems only to work for me if copy and paste into browser)

In contrast, HLS Therapeutics licensed Vascepa (also pre-REDUCE-IT completion) in Sept. 2017 (31 months later) and have already received regulatory approval, negotiated pricing, and recently obtained public reimbursement in Quebec.
https://www.hlstherapeutics.com/en-us/business-development-us/
https://hlstherapeutics.investorroom.com/news?item=16
https://hlstherapeutics.investorroom.com/2022-04-26-HLS-Therapeutics-completes-negotiations-with-pCPA-for-Vascepa-R
https://hlstherapeutics.investorroom.com/2022-05-24-HLS-Therapeutics-Obtains-Public-Reimbursement-for-Vascepa-R-in-Quebec

I suspect a BP partner in China could have moved things forward much more quickly.

[dogn]

Lizzy, have you seen this Edding Group Co. Ltd. "Application Proof" in draft form?

Incorporated in the Cayman Islands?
Extensively redacted

pdf p. 141/document p.133:
(a) this document must be issued on or before March [21], 2022;
(b) our Company must [REDACTED] on the Stock Exchange on or before March [31], 2022;
(c) this document contains the financial information for the year ended December 31, 2021

https://www1.hkexnews.hk/app/sehk/2021/104071/documents/sehk21121501528.pdf